Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Kohl's Corporation (KSS) Price & Performance

Cytokinetics IncTrade
Kohl's CorporationTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Kohl's Corporation — how do they compare? Cytokinetics Inc trades at $76.46 (market cap $10.63B), while Kohl's Corporation trades at $18.84 (market cap $2.10B). The key difference: Cytokinetics Inc is far larger — about 5.1× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.7% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.

CYTKKSS
Market Cap
$10.63B$2.10B
Sector
TechnologyConsumer Cyclical
52-Week High
$87.26$24.71
52-Week Low
$34.31$11.72
Enterprise Value
$10.74B$8.20B
Dividend Yield
2.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

Kohl's Corporation

Kohl's stock trades at $19.04, down 1.35% with a bullish technical signal despite recent weakness. The company shows improving fundamentals with three consecutive earnings beats and positive cash flow projections for 2026. Valuation metrics appear attractive with P/E of 7.77 and P/B of 0.52, while recent management changes and proprietary brand growth provide operational momentum.

Kohl's presents a turnaround opportunity with undervalued metrics and improving operational execution, though declining revenue and thin margins pose significant challenges. Analyst consensus remains cautious with a $16.75 price target below current levels, reflecting concerns about sustained growth in a competitive retail environment.

Returns comparison

Trailing returns across standard periods

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Kohl's Corporation

Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.

Read more on KSS